A Prospective Multicenter Post Approval Study to Evaluate the Long-term Safety and Efficacy of the Resolute Integrity in the Japanese All-comers Patients With Coronary Artery Disease

Trial Profile

A Prospective Multicenter Post Approval Study to Evaluate the Long-term Safety and Efficacy of the Resolute Integrity in the Japanese All-comers Patients With Coronary Artery Disease

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Feb 2017

At a glance

  • Drugs Zotarolimus (Primary)
  • Indications Coronary artery disease
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PROPEL
  • Most Recent Events

    • 26 Jan 2017 Status changed from discontinued to completed.
    • 25 Mar 2016 Status changed from active, no longer recruiting to discontinued.
    • 06 Apr 2015 Planned End Date changed from 1 Oct 2016 to 1 Sep 2017 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top